Ketamine for the treatment of major depression: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression. However, uncertainties remain regarding comparative efficacy, dosage, and the time course of response. Methods: In this systematic review and meta-analysis, we searched Embase, Medline, Pubmed, PsycINFO, and CENTRAL up to April 13, 2023, for randomised controlled trials (RCTs) investigating ketamine for depression. Two investigators independently assessed study eligibility and risk of bias and extracted the data on depression severity scores, response and remission rates, and all-cause dropouts. Multivariable mixed-effects meta-regressions incorporated drug formulation (racemic (Rac) or esketamine (Esket)) and dose (Low or High) as covariates. Treatment effects were assessed: immediately following the first dose, during further repeated dosing, and follow-up after the final dose of a treatment course. This study is registered with PROSPERO (CRD42021221157). Findings: The systematic review identified 687 articles, of which 49 RCTs were eligible for analysis, comprising 3299 participants. Standardised mean differences (95% confidence intervals) immediately following the first/single treatment were moderate-high for all conditions (Rac-High: -0.73, -0.91 to -0.56; Esket-High: -0.48, -0.75 to -0.20; Rac-Low: -0.33, -0.54 to -0.12; Esket-Low: -0.55, -0.87 to -0.24). Ongoing effects during repeated dosing were significantly greater than the control for Rac-High (-0.61; -1.02 to -0.20) and Rac-Low (-0.55, -1.09 to -0.00), but not Esket-Low (-0.15, -0.49 to 0.19) or Esket-High (-0.22, -0.54 to 0.10). At follow-up effects remained significant for racemic ketamine (-0.65; -1.23 to -0.07) but not esketamine (-0.33; -0.96 to 0.31). All-cause dropout was similar between experiment and control conditions for both formulations combined (Odds Ratio = 1.18, 0.85-1.64). Overall heterogeneity varied from 5.7% to 87.6. Interpretation: Our findings suggested that effect sizes for depression severity, as well as response and remission rates, were numerically greater for racemic ketamine than esketamine. Higher doses were more effective than low doses. Differences were evident in initial effects, ongoing treatment, and lasting effects after the final dose. Funding: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationPopova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Research works printed but not linked: 25
- Han, 2016, Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies, Neuropsychiatr Dis Treat, 12, 2859, 10.2147/NDT.S117146 · DOI
- Loo, 2023, Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial, B J Psych, 1
- Hartberg, 2018, Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study, Psychopharmacology, 235, 393, 10.1007/s00213-017-4786-3 · DOI
- Loo, 2016, Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression, Acta Psychiatr Scand, 134, 48, 10.1111/acps.12572 · DOI · Paper page
- Short, 2018, Side-effects associated with ketamine use in depression: a systematic review, Lancet Psychiatry, 5, 65, 10.1016/S2215-0366(17)30272-9 · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, 10.1371/journal.pmed.1000097 · DOI · Paper page
- Page, 2021, Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement, J Clin Epidemiol, 134, 103, 10.1016/j.jclinepi.2021.02.003 · DOI · Paper page
- Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
- Glue, 2021, Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review, Eur J Clin Pharmacol, 77, 671, 10.1007/s00228-020-03047-z · DOI
- Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
- Sos, 2013, Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression, Neuroendocrinol Lett, 34, 101
- Lai, 2014, Pilot dose–response trial of iv ketamine in treatment-resistant depression, World J Biol Psychiatry, 15, 579, 10.3109/15622975.2014.922697 · DOI · Paper page
- Singh, 2016, Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study, Biol Psychiatry, 80, 424, 10.1016/j.biopsych.2015.10.018 · DOI · Paper page
- Su, 2017, Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression, Neuropsychopharmacology, 42, 2482, 10.1038/npp.2017.94 · DOI · Paper page
- Cao, 2018, Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG, IEEE Trans Biomed Eng, 66, 1668, 10.1109/TBME.2018.2877651 · DOI · Paper page
- Domany, 2019, Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study, Br J Psychiatry, 214, 20, 10.1192/bjp.2018.196 · DOI
- Shiroma, 2020, A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression, Transl Psychiatry, 10, 1, 10.1038/s41398-020-00897-0 · DOI
- Sumner, 2020, Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder, Biol Psychiatry, 5, 45
- Dwyer, 2021, Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial, Am J Psychiatry, 178, 352, 10.1176/appi.ajp.2020.20010018 · DOI · Paper page
- Lijffijt, 2022, Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial, Neuropsychopharmacology, 47, 1088, 10.1038/s41386-021-01242-9 · DOI
- Sinyor, 2018, Ketamine augmentation for major depressive disorder and suicidal ideation: preliminary experience in an inpatient psychiatry setting, J Affect Disord, 241, 103, 10.1016/j.jad.2018.07.073 · DOI
- Gallagher, 2020, Ketamine as an adjunctive therapy for major depression-a randomised controlled pragmatic pilot trial (Karma-Dep Trial), HRB Open Res, 3, 90, 10.12688/hrbopenres.13182.1 · DOI
- Ahmed, 2023, Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: a double-blind randomized trial, J Affect Disord, 325, 127, 10.1016/j.jad.2023.01.005 · DOI
- Singh, 2020, Approval of esketamine for treatment-resistant depression, Lancet Psychiatry, 7, 232, 10.1016/S2215-0366(19)30533-4 · DOI · Paper page
- Zhang, 2014, R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine, Pharmacol Biochem Behav, 116, 137, 10.1016/j.pbb.2013.11.033 · DOI · Paper page
Cited by
Management of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
Mandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
“More specifically, the standardized mean differences we estimated are consistent with the results reported by Nikolin et al. [48], which indicate standardized mean differences of around 0.2 for outcomes during a treatment course (1–4 weeks) with esketamine.”
Influential
Metadata
- Authors
- Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C.
- Venue
- eClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 62
- Pages
- 102127
- ISSN
- 2589-5370 (ISSN-L)
- OpenAlex
- W4385556714
- Cited by
- 172
- References
- 45
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Yale University
- Canadian Institutes of Health Research
- Ontario Ministry of Health and Long-Term Care
- National Health and Medical Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine for the treatment of major depression: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/j.eclinm.2023.102127
- The paper
- Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023). Ketamine for the treatment of major depression: a systematic review and meta-analysis. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.102127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.